Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lympho...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Byrd, John C., Kipps, Thomas J., Flinn, Ian W., Castro, Januaro, Lin, Thomas S., Wierda, William, Heerema, Nyla, Woodworth, James, Hughes, Steve, Tangri, Shabnam, Harris, Sarah, Wynne, Dee, Molina, Arturo, Leigh, Bryan, O'Brien, Susan
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2010
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2810983/
https://ncbi.nlm.nih.gov/pubmed/19843887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-08-237727
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars